Publications by authors named "Felix Oestereich"

Article Synopsis
  • * Results showed a significant reduction in the Psoriasis Area and Severity Index (PASI) after 3 and 18 months, with many patients achieving low PASI scores, indicating effective treatment.
  • * Improvements in quality of life were noted, and no patients discontinued treatment due to adverse events, suggesting that tildrakizumab has a strong safety profile in a real-world setting.
View Article and Find Full Text PDF
Article Synopsis
  • High levels of LDL cholesterol are linked to a higher risk of Alzheimer's disease, and changes in CETP activity influence cholesterol levels and cognitive function.
  • Pharmacological inhibitors of CETP, like evacetrapib, show potential for treating Alzheimer's by effectively lowering LDL cholesterol.
  • Evacetrapib can cross the blood-brain barrier and reach brain tissue, making it a promising candidate in addressing cholesterol-related issues in Alzheimer's patients.
View Article and Find Full Text PDF

The cholesteryl ester transfer protein (CETP) is a lipid transfer protein responsible for the exchange of cholesteryl esters and triglycerides between lipoproteins. Decreased CETP activity is associated with longevity, cardiovascular health, and maintenance of good cognitive performance. Interestingly, mice lack the CETP-encoding gene and have very low levels of LDL particles compared with humans.

View Article and Find Full Text PDF

Proteases, sharp yet unforgivable tools of every cell, require tight regulation to ensure specific non-aberrant cleavages. The relatively recent discovered class of intramembrane proteases has gained increasing interest due to their involvement in important signaling pathways linking them to diseases including Alzheimer's disease and cancer. Despite tremendous efforts, their regulatory mechanisms have only started to unravel.

View Article and Find Full Text PDF

The amyloid precursor protein (APP) is an ubiquitously expressed cell surface protein and a key molecule in the etiology of Alzheimer disease. Amyloidogenic processing of APP through secretases leads to the generation of toxic amyloid β (Aβ) peptides, which are regarded as the molecular cause of the disease. We report here an alternative processing pathway of APP through the mammalian intramembrane rhomboid protease RHBDL4.

View Article and Find Full Text PDF

Amyloid-β (Aβ) peptides are likely the molecular cause of neurodegeneration observed in Alzheimer's disease. In the brain, Aβ42 and Aβ40 are toxic and the most important proteolytic fragments generated through sequential processing of the amyloid precursor protein (APP) by β- and γ-secretases. Impeding the generation of Aβ42 and Aβ40 is thus considered as a promising strategy to prevent Alzheimer's disease.

View Article and Find Full Text PDF